^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CIMAbior (rituximab biosimilar)

    i
    Other names: 1B8
    Associations

    News

    Trials
    Company:
    Center of Molecular Immunology
    Drug class:
    CD20 inhibitor
    Related drugs:
    Associations

    News

    Trials
    over1year
    Potent immunomodulatory and antitumor effect of anti-CD20-IL2no-alpha tri-functional immunocytokine for cancer therapy. (PubMed, Front Immunol)
    The anti-CD20 antibody rituximab (RTX) has substantially improved outcomes of patients with B-cell lymphomas, although more efficient therapies are needed for refractory or relapsing lymphomas. Anti-CD20-IL2no-alpha (hIgG1) strongly expanded NK and CD8+ T cells but not Tregs in tumor-bearing mice. These findings suggest that anti-CD20-IL2no-alpha could represent an alternative treatment for B cell lymphoma patients, mainly those refractory to RTX therapy.
    Journal • Immunomodulating
    |
    CD8 (cluster of differentiation 8) • IL2RA (Interleukin 2 receptor, alpha)
    |
    CD20 expression • IL2RA expression
    |
    Rituxan (rituximab) • CIMAbior (rituximab biosimilar)